Compare Howmet Aerospace Inc (HWM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Recursion Pharmaceuticals Inc — how do they compare? Howmet Aerospace Inc trades at $277.1 (market cap $108.82B), while Recursion Pharmaceuticals Inc trades at $3.04 (market cap $1.53B). The key difference: Howmet Aerospace Inc is far larger — about 71.1× Recursion Pharmaceuticals Inc's market cap, and Howmet Aerospace Inc pays a 0.18% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| HWM | RXRX | |
|---|---|---|
Market Cap | $108.82B | $1.53B |
Sector | Industrials | Health |
52-Week High | $283.23 | $6.79 |
52-Week Low | $171.00 | $2.84 |
Enterprise Value | $111.07B | $946.50M |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $271.98, down 0.17% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.22 exceeding the $1.11 estimate. Financials show robust profitability, including a 20.22% net income margin and 33.98% ROE, though valuation ratios like a P/E of 63.21 appear elevated. Recent news highlights commercial aerospace demand driving growth, with shares gaining 249% since May 2024 according to FXEmpire on July 15, 2026.
The outlook remains positive due to sustained aerospace demand and analyst consensus favoring buys, but risks include high valuation sensitivity and market volatility. Upside to the $317.63 price target offers potential, yet investors should weigh premium multiples against earnings growth momentum and sector cyclicality.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
